Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Methylphenidate

Methylphenidate

Methylphenidate is a central nervous stimulant used to treat attention-deficit hyperactivty disorder (ADHD) and narcolepsy.
It works by increasing the availability of certain neurotransmitters, such as dopamine and norepinephrine, in the brain.
PubCompare.ai optimizes Methylphenidate research by helping users find the most reliable protocols from the literature, preprints, and patents.
Its AI-driven comparisons enhance reproducibility and accuaracy, ensuring you identify the best products and methodologies for your Methylphenidate studies.

Most cited protocols related to «Methylphenidate»

1
Early Parkinson's Disease Cohort Study
Cited 48 times
PD and HC subjects of similar age and gender from 24 study sites in the US (18), Europe (5) and Australia (1) were enrolled after obtaining informed consent. We acknowledge that the early PD cohort likely includes a small number of subjects with other DAT deficit parkinsonian syndromes such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and cortical basal syndrome (CBS), which may be indistinguishable from PD at the earliest stages of disease. At each study visit, the investigators reassess the subject diagnosis to identify any non‐PD subjects.
This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines after approval of the local ethics committees of the participating sites. At enrollment, PD subjects were required to be age 30 years or older, untreated with PD medications (levodopa, dopamine agonists, MAO‐B inhibitors, or amantadine), within 2 years of diagnosis, Hoehn and Yahr <3, and to have either at least two of resting tremor, bradykinesia, or rigidity (must have either resting tremor or bradykinesia) or a single asymmetric resting tremor or asymmetric bradykinesia. All PD subjects underwent dopamine transporter (DAT) imaging with 123I Ioflupane or vesicular monoamine transporter (VMAT‐2) imaging with 18F AV133 (Australia only) and were only eligible if DAT or VMAT‐2 imaging demonstrated dopaminergic deficit consistent with PD in addition to clinical features of the disease. Study investigators evaluated enrolled PD subjects to assess absence of current or imminent (6 months) disability requiring PD medications, though subjects could initiate PD medications at any time after enrollment if the subject or investigator deemed it clinically necessary. Those subjects screened as potential PD subjects who were ineligible due to DAT or VMAT‐2 scans without evidence of dopaminergic deficit (SWEDD) were eligible to be enrolled in a SWEDD cohort.4 HC subjects were required to be age 30 years or older without an active, clinically significant neurological disorder or a first‐degree relative with PD. All enrolled subjects agreed to complete all study evaluations, including lumbar puncture.
PD and SWEDD subjects were excluded if they had a clinical diagnosis of dementia or had taken PD medications within 60 days of baseline or for longer than 60 days in total. HC subjects were excluded if they had a Montreal Cognitive Assessment (MoCA) total score ≤26. All subjects were excluded if they were treated with neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative within 6 months or were currently treated with anticoagulants that might preclude safe completion of the lumbar puncture.
Marek K., Chowdhury S., Siderowf A., Lasch S., Coffey C.S., Caspell‐Garcia C., Simuni T., Jennings D., Tanner C.M., Trojanowski J.Q., Shaw L.M., Seibyl J., Schuff N., Singleton A., Kieburtz K., Toga A.W., Mollenhauer B., Galasko D., Chahine L.M., Weintraub D., Foroud T., Tosun‐Turgut D., Poston K., Arnedo V., Frasier M, & Sherer T. (2018). The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 5(12), 1460-1477.
Publication 2018
123I-ioflupane Amantadine Amphetamine Anticoagulants Antipsychotic Agents Bradykinesia Cortex, Cerebral Dementia Diagnosis Disabled Persons Dopamine Agonists Gender Hydrochloride, Dopamine Levodopa Methyldopa Methylphenidate Metoclopramide Monoamine Oxidase Inhibitors Multiple System Atrophy Muscle Rigidity Nervous System Disorder Parkinsonian Disorders Pharmaceutical Preparations Progressive Supranuclear Palsy Punctures, Lumbar Radionuclide Imaging Regional Ethics Committees Reserpine Resting Tremor SLC6A3 protein, human Syndrome Vesicular Monoamine Transport Proteins Volumetric-Modulated Arc Therapy
2
Validation of Register-Based ADHD Diagnosis
Cited 15 times
Patients obtaining a diagnosis of ADHD between 1987 and 2009 were identified in the patient register (ICD-9: 314; ICD-10: F90). All psychiatric discharges were included and no distinction was made between primary and secondary diagnoses. Patients treated with stimulant or non-stimulant medication for ADHD (methylphenidate [N06BA04]; atomoxetin [N06BA09]; amphetamine [N06BA01]; dexamphetamine [N06BA02]) at any time between July 2005 and December 2009 were identified via the Prescribed Drug Register and also counted as ADHD probands. In the current study, patients aged 3–65 years at the time of the first ADHD diagnosis (or first prescription of stimulant or non-stimulant medication for ADHD) were included as probands.
National guidelines for medication of ADHD, issued by the Swedish National Board of Health and Welfare in 2002, states that medication should be reserved for cases where other supportive interventions have failed. This indicates that individuals with ADHD drug prescriptions represent the more severe cases of ADHD. The authority to prescribe ADHD drugs in Sweden is restricted to specialist physicians familiar with the treatment of this disorder.
We used psychiatric symptom data of 20,000 twins (born 1992–2001) from the Swedish Twin Register to explore the validity of the register-based ADHD diagnosis. ADHD symptoms in twins were assessed using the Autism – Tics, ADHD, and other Comorbidities inventory (A-TAC), which covers 96 specific child psychiatric symptoms. Two studies with extensive psychometric analyses found excellent validity for the A-TAC ADHD-measures (7 (link)). The mean ADHD score of the twins with our register-based definition of ADHD (m=9.05, SD=5.32) was substantially higher (Cohen's d=1.74) than in the total sample (m=1.73, SD=2.68). In addition, about 70% of the twins with an ADHD diagnosis were screen-positive for parent-rated ADHD. Very similar results were obtained when these validity checks were restricted to either ADHD cases identified through ICD diagnoses (i.e., Patient Register) or pharmacological ADHD treatments (i.e., Prescribed Drug Register).
Larsson H., Rydén E., Boman M., Långström N., Lichtenstein P, & Landén M. (2013). Does attention deficit hyperactivity disorder share etiologic factors with bipolar disorder and schizophrenia?. The British journal of psychiatry : the journal of mental science, 203, 103-106.
Publication 2013
Amphetamines Autistic Disorder Child Childbirth Dextroamphetamine Diagnosis Disorder, Attention Deficit-Hyperactivity Methylphenidate Parent Patients Pharmaceutical Preparations Pharmacotherapy Physicians Psychometrics Tic Disorder Twins
3
Extradural EEG Recordings of Methylphenidate Effects
Cited 9 times
Extradural electroencephalogram electrodes were surgically implanted at least 7 days prior to recording. General anesthesia was induced with xylazine (5-10 mg/kg intraperitoneal) and ketamine (50-100 mg/kg intraperitoneal), and supplemented with isoflurane (1-2%). A microdrill was used to make four holes at the following stereotactic coordinates: A0L0, A6L3, A6L-3, and A10L2 relative to the lambda.12 (link) Polytetrafluoroethylene coated, 200 μm diameter stainless steel electrode wires (A-M Systems, Sequim, WA) were inserted and secured with small stainless steel screws, and permanently fixed with dental acrylic cement. Carprofen (5 mg/kg subcutaneous) was administered for analgesia on the day of surgery, as well as on postoperative days 1 and 2.
The potential difference between electrodes A0L0 and A6L3, or between electrodes A0L0 and A6L-3 (whichever gave less motion artifact), was referenced to A10L2 and recorded using a QP511 Quad AC Amplifier System (Grass Instruments, West Warwick, RI) and a USB-6009 14-bit data acquisition board (National Instruments, Austin, TX). Data was filtered between 0.3-100 Hz. No line filter was used. The sampling rate was 512 Hz.
After baseline recordings were taken for 10 min while awake, rats were anesthetized with isoflurane and placed in the anesthetizing chamber. Although we initially attempted to perform the electroencephalogram experiments simultaneously with the behavioral experiments described above, we found that the righting attempts produced too many motion artifacts. Therefore we performed the electroencephalogram experiments in the prone position with the isoflurane dose fixed at 1.0%. These modifications allowed us to minimize electroencephalogram motion artifacts without restraining the animals. After a minimum isoflurane exposure of 40 min, normal saline was administered and the temperature probe was removed. Five minutes later, methylphenidate was administered.
Spectral analysis was performed using Matlab 7.11 (Mathworks, Natick, MA) and the Chronux software (Cold Spring Harbor, NY).13 (link) Spectrograms were calculated using sliding windows of 2-s duration stepped through 0.05 s. For each window, multitaper spectrum estimation was performed using five tapers. The resulting spectral estimates have a bandwidth of ±1.5 Hz. Mean power spectra were compared before and after methylphenidate administration using Kolmogorov-Smirnov tests.14 To determine the difference between two spectra, a two-sample Kolmogorov-Smirnov test15 was performed on the spectral power as a function of frequency computed from the 30 windows in the premethylphenidate and postmethylphenidate periods. We used a Bonferroni correction to adjust the significance level for multiple hypothesis-testing.
Solt K., Cotten J.F., Cimenser A., Wong K.F., Chemali J.J, & Brown E.N. (2011). Methylphenidate Actively Induces Emergence from General Anesthesia. Anesthesiology, 115(4), 791-803.
Publication 2011
Animals austin carprofen Cold Temperature Dental Cements Electroencephalography General Anesthesia Isoflurane Ketamine Management, Pain Methylphenidate Normal Saline Operative Surgical Procedures Poaceae Polytetrafluoroethylene Rattus Stainless Steel Surgery, Day Xylazine
4
Qualitative Analysis of NICE ADHD Appraisal
Cited 9 times
A qualitative study was done of NICE Technology Appraisal No. 98, "Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (Review of Technology Appraisal 13)" [3 ]. The study focused on policy-relevant aspects and had descriptive, explorative, and explanatory elements.
Its initial phase consisted of defining a theoretical framework for analysis. This included a description of NICE technology appraisal processes, which fell in a period of substantial upgrade and definition of "reference case" analysis by NICE [7 ,8 ]. During this phase, a thematic framework was defined, comprising use of the "accountability for reasonableness" concept as a process benchmark [9 ,10 (link)], a critique of the technology assessment report underlying the appraisal, as well as a review of the clinical and economic literature on attention-deficit/hyperactivity disorder [11 ].
Its second phase comprised data collection employing a number of closely related strategies, including retrieval and analysis of documents related to the ADHD appraisal which were posted on the NICE website. Scientific articles cited in these documents were obtained for analysis. This was supplemented by literature searches (using the PubMed and, via EBSCO host services, the Business Source Elite databases as well as Google Scholar) for articles on ADHD diagnosis, treatment, compliance, cost, and cost-effectiveness, which were complemented by a search for relevant abstracts presented at international meetings in the fields of psychiatry and health economics. Documents were indexed using categories including study type, product tested, and subject matter (e.g., "treatment compliance") for further analysis and interpretation.
The analysis reported here is part of this more comprehensive study of NICE appraisal processes by the same author [11 ], and it is focused on the underlying Technology Assessment Report [4 ]. The purpose of the present paper is to shed light on the validity of the conclusions offered by NICE; it should be emphasized that it is not intended to assign responsibility for any identified problems to particular actors (such as NICE, its committees, or the assessment team). Unless specified otherwise, the following citations will refer to the Technology Assessment Report ("TAR" [4 ]), which was subsequently published as a full paper in the Health Technology Assessment monograph series of the NHS R&D HTA Programme [12 (link)], apparently unchanged.
, & Schlander M. (2008). The NICE ADHD health technology assessment: A review and critique. Child and Adolescent Psychiatry and Mental Health, 2, 1.
Full text: Click here
Publication 2008
Adolescent Atomoxetine Child Dextroamphetamine Diagnosis Disorder, Attention Deficit-Hyperactivity Light Methylphenidate Technology Assessment Technology Assessment, Biomedical
5
Oral Methylphenidate and Cocaine Dosing Protocol
Cited 8 times
(±)-Methylphenidate hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in tap water (1.5 mg/ml) and injected into an oyster cracker to attain a dose of 1.5 mg/kg for oral consumption. Oyster crackers containing tap water (1.0 ml/kg) were used for vehicle control. To mimic a clinical dosing schedule for ADHD treatment (American Academy of Pediatrics Committee on Children With Disabilities and Committee on Drugs, 1996 (link)), groups from each strain were treated Monday-Friday with vehicle or methylphenidate from P28–P55. On days that overlapped with visual discrimination testing (Experiment 1), rats were treated 30-min prior to start of sessions. Amount of time to consume daily oyster crackers averaged < 3 min. A 1.5 mg/kg oral dose of methylphenidate ensured that therapeutically relevant plasma drug levels were achieved and the 30-min pretreatment time ensured that plasma drug levels peaked prior to the start of behavioral sessions (Kuczenski and Segal, 2002 (link)).
Cocaine hydrochloride (NIDA, Bethesda, Maryland, USA) was dissolved in 0.9% sterile saline containing 3 IU heparin/ml. A cocaine unit dose of 0.3 mg/kg (0.8 mg/ml) was used for training. Additionally, cocaine unit doses ranging from 0.003 to 1.0 mg/kg were used to determine dose-response curves. A constant drug delivery time of 1.2 s/100g body weight was maintained by adjusting cocaine concentration for each dose.
For [3H]DA uptake assays, desipramine hydrochloride, paroxetine hydrochloride, nomifensine maleate, ethylenediaminetetraacetic acid (EDTA), sucrose, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-hydroxytyramine (DA), sodium chloride and magnesium sulfate were purchased from Sigma-Aldrich Co. (St. Louis, MO). [3H]DA (Dihydroxyphenylethylamine,3,4-[7-3H]; specific activity, 30.3 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences Inc. (Boston, MA). α-d-Glucose, l-ascorbic acid, and monobasic potassium phosphate were purchased from Aldrich Chemical Co. (Milwaukee, WI), AnalaR-BHD Ltd. (Poole, UK) and Mallinckrodt (St. Louis, MO), respectively. All other chemicals in the assay buffer were purchased from Fisher Scientific Co. (Pittsburgh, PA).
Harvey R.C., Sen S., Deaciuc A., Dwoskin L.P, & Kantak K.M. (2010). Methylphenidate Treatment in Adolescent Rats with an Attention Deficit/Hyperactivity Disorder Phenotype: Cocaine Addiction Vulnerability and Dopamine Transporter Function. Neuropsychopharmacology, 36(4), 837-847.
Publication 2010
Acids Ascorbic Acid Biological Assay Body Weight Buffers Child Cocaine Disabled Persons Discrimination, Psychology Disorder, Attention Deficit-Hyperactivity Dopamine Drug Delivery Systems Edetic Acid Glucose Heparin HEPES Hydrochloride, Cocaine Hydrochloride, Desipramine Maleate, Nomifensine Methylphenidate Methylphenidate Hydrochloride N-nitrosoiminodiacetic acid Normal Saline Oysters Paroxetine Hydrochloride Pharmaceutical Preparations Plasma potassium phosphate, monobasic Rattus Sodium Chloride Sterility, Reproductive Strains Sucrose Sulfate, Magnesium Treatment Protocols

Most recents protocols related to «Methylphenidate»

1
Stimulant Abuse and Academic Impact
This adaptive section first elicited information regarding the perception of the impact of stimulant abuse on academic performance (scored on a 5-point Likert like scale, ranging from “Strongly disagree” to “Strongly agree”) and whether the student had abused stimulants (yes/no). Stimulant abuse in this study was considered as the nonprescribed use of amphetamine, dextroamphetamine, and/or methylphenidate. For students who answered “yes,” the following additional data were collected: the lifetime frequency of use, recency of use, reason behind the use, and trial of withdrawal. The trial of withdrawal was considered based on acting on and intention to withdraw.
Bahlaq M.A., Ramadan I.K., Abalkhail B., Mirza A.A., Ahmed M.K., Alraddadi K.S, & Kadi M. (2023). Burnout, Stress, and Stimulant Abuse among Medical and Dental Students in the Western Region of Saudi Arabia: An Analytical Study. Saudi Journal of Medicine & Medical Sciences, 11(1), 44-53.
Publication 2023
Acclimatization Amphetamines Central Nervous System Stimulants Dextroamphetamine Drug Abuse Methylphenidate Student
2
Epidemiological Survey of Student Drug Use
It is a 37-item questionnaire created to aid in collecting epidemiological data on drug abuse among students and adolescents in many parts of the world.20 (link) It enquires about psychoactive substances: alcohol, tobacco, and other illicit substances such as cocaine, cannabis, hallucinogens, opioids, and sedatives. The questionnaire was slightly modified by adding specific examples of drugs pertinent to this setting to the drug classes, using common street names. For example, regarding amphetamine-type stimulants (ATS), different names like methylphenidate (Ritalin), khat, speed, and crystal meth were included. In addition, a fictitious drug was included in the list of substances to check participants’ responses regarding overreporting. Some of the information obtained included lifetime use, past 12 months, current use, type of substance, and age at onset.
Olashore A.A., Paruk S., Brooks M, & Chiliza B. (2023). Psychoactive Substance Use Disorder in HIV-Infected Adolescents in Botswana: A Comparison Between the Congenitally Infected and Behaviorally Infected Adolescents. Substance Abuse: Research and Treatment, 17, 11782218231152818.
Publication 2023
Adolescent Amphetamines Cannabis Catha edulis Central Nervous System Stimulants Cocaine Drug Abuse Ethanol Hallucinogens Methamphetamine Methylphenidate Opioids Pharmaceutical Preparations Ritalin Sedatives Student Tobacco Products
3
Contraindications and Participant Screening for tDCS
Contraindications for tDCS treatment include patients with metal device implants (such as the cochlear implant, the artery clamp, and the pacemaker); history of brain trauma or cerebrovascular accident, intracranial hypertension, skull defects, epilepsy, and other serious neurological, circulatory, endocrine, and other physical diseases; audio-visual impairments and color blindness, color weakness, or narrow-angle glaucoma. The abovementioned contraindications were excluded by inquiring and collecting medical history, conducting an electrocardiogram (ECG), electroencephalogram (EEG), cranial CT, and blood routine and biochemical examinations. All subjects were evaluated for no comorbidities of other mental disorders with validated screening and diagnostic instruments: DSM-5 and ICD-10, such as substance abuse/dependence, conduct disorders, personality disorders, autism, Tourette's disorder, and obsessive-compulsive disorder. Patients who had used any medication (methylphenidate, atomoxetine, etc.) in the past and recently to treat ADHD or who received other brain stimulation (transcranial magnetic stimulation, electroconvulsive shock, etc.) were also excluded.
To calculate the sample size, we used G*Power (37 (link)) with the following settings: effect size f = 0.25, α level = 0.05, power = 0.8, and correlation among repeated measures = 0.5. The minimum sample size was found to be n = 44. To prevent a potentially large number of dropouts, a total of 56 subjects were recruited, including 33 boys and 23 girls. A completely randomized experimental design was adopted, and the subjects were divided into two groups according to age through a random number table: the HD-tDCS group and the Sham group (Figure 1). A general information questionnaire was developed, including age, gender, educational years, whether the subject comes from a single-parent family, age of onset, and disease. Both the participants and their guardians were informed of this study, and signed informed consent was obtained. The study was approved by the Ethics Committee of Zhenjiang Mental Health Center. This trial was conducted in accordance with the Declaration of Helsinki and the Consolidated Standards of Reporting Trials (CONSORT) guidelines (38 (link)).
Wang Y.C., Liu J., Wu Y.C., Wei Y., Xie H.J., Zhang T, & Zhang Z. (2023). A randomized, sham-controlled trial of high-definition transcranial direct current stimulation on the right orbital frontal cortex in children and adolescents with attention-deficit hyperactivity disorder. Frontiers in Psychiatry, 14, 987093.
Full text: Click here
Publication 2023
Angle Closure Glaucoma Arteries Asthenia Atomoxetine Autistic Disorder Blindness, Color BLOOD Boys Brain Cardiovascular System Cerebrovascular Accident Conduct Disorder Cranium Diagnosis Disorder, Attention Deficit-Hyperactivity Drug Abuse Electrocardiography Electroconvulsive Shock Electroencephalography Epilepsy Ethics Committees Gender Gilles de la Tourette Syndrome Implantations, Cochlear Legal Guardians Medical Devices Mental Disorders Mental Health Metals Methylphenidate Obsessive-Compulsive Disorder Pacemaker, Artificial Cardiac Patients Personality Disorders Pharmaceutical Preparations Physical Examination Single-Parent Family Stimulation, Transcranial Magnetic Substance Abuse Substance Dependence System, Endocrine Transcranial Direct Current Stimulation Traumatic Brain Injury Woman
4
Mental Health Assessment in Brazilians with DM1
An online questionnaire was used, consisting of questions developed by the study researchers, and belonging to the DSM-5 Level 1 Cross-sectional Symptom Scale [24 ]. The questionnaire contained 14 multiple-choice questions and a simple subjective question, referring to the age of the participants. The first two questions referred to accepting to participate in the research and being an adult with DM1; the other questions in the questionnaire were divided into three axes, namely:

Sociodemographic: questions related to age, gender and region of Brazil in which they resided;

Mental health: the DSM-5 Level 1 Cross-sectional Symptom Scale [24 ] was used, adapted to assess only questions from the psychiatric domains related to anxiety, anger, depression, sleep disorders and substance use (considering only the medication use). In the question regarding the use of medications, the use of any of the following medications on their own was considered; that is, without a medical prescription, in larger amounts or for a longer period than prescribed (e.g., analgesics (such as paracetamol, codeine), high-stimulants (such as methylphenidate or amphetamines), sedatives or tranquilizers (such as sleeping pills or diazepam) or drugs such as marijuana, cocaine or crack, synthetic drugs (such as ecstasy), hallucinogens (such as LSD), heroin, inhalants or solvents (such as cola) or methamphetamine (or other stimulants)). The scale score ranged from zero to four, with zero corresponding to mild and four corresponding to severe;

Physical activity: questions regarding the practice of physical activity assessed the occurrence of physical activity before and during social isolation.

Uliana G.C., Gomes D.L., Galvão O.F, & Paracampo C.C. (2023). Changes in Physical Activity Associated with Mental Health in People with Type 1 Diabetes during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 20(4), 3081.
Full text: Click here
Publication 2023
Acetaminophen Adult Amphetamines Analgesics Anger Anxiety Cannabis sativa Central Nervous System Stimulants Cocaine Codeine Cola Diazepam Epistropheus Gender Hallucinogens Heroin Inhalation Drug Administration MDMA Mental Health Methamphetamine Methylphenidate Pharmaceutical Preparations Sedatives Sleep Disorders Sleeping Pills Solvents Substance Use Synthetic Drugs Tranquilizing Agents
5
ADHD and Neurodevelopment Outcomes after Anesthesia
All outcomes were prespecified. The primary outcome of this study was ADHD. Based on previous validation studies, ADHD was defined as at least a principal diagnosis of ICD-10 code F90.X after 72 months old. Using a principal diagnosis based on the ICD-10 code to define ADHD had high sensitivity (0.96 to 0.97), specificity (0.98 to 0.99), and positive predictive value (0.83 to 0.98).13 (link)
For the sensitivity analysis, alternative definitions of ADHD were defined. First, a recurrent ADHD 1 year apart was defined as 2 principal diagnoses of ICD-10 codes F90.X after 72 months old that were 1 year apart. Second, a wide-ranging ADHD was defined as at least a principal or second diagnosis of ICD-10 code F90.X after 72 months old. Third, ADHD with medication was defined as at least a principal diagnosis of ICD-10 code F90.X after 72 months old with a prescription of methylphenidate.
In addition, the secondary outcome was the association with the K-ASQ results to estimate neurodevelopment after exposure to general anesthesia with ETI. The K-ASQ consists of 5 domains: communication, gross motor skills, fine motor skills, problem-solving, and personal-social interrelation. The results of each domain of the K-ASQ were stratified as appropriate, need for follow-up, and recommendations for further evaluation. The results of need for follow-up and recommendation for further evaluation mean scores below −1 standard deviation (SD) for age and below −2 SD for age, respectively. For analysis of the K-ASQ results, the two outcomes of interest were: 1) recommendations for further evaluation and 2) the sum of the need for follow-up and recommendation for further evaluation.
All outcomes were identified for at least 1 year (window period) after the index date.
Song J.Y., Cha H.R., Lee S.W., Ha E.K., Kim J.H, & Han M.Y. (2023). Association Between Receipt of General Anesthesia During Childhood and Attention Deficit Hyperactive Disorder and Neurodevelopment. Journal of Korean Medical Science, 38(6), e42.
Publication 2023
Diagnosis Disorder, Attention Deficit-Hyperactivity General Anesthesia Hypersensitivity Methylphenidate Motor Skills Pharmaceutical Preparations

Top products related to «Methylphenidate»

1
Methylphenidate by Merck Group
Sourced in Germany, United States
Methylphenidate is a chemical compound used in laboratory settings. It is a central nervous system stimulant that can be used in the research and development of various pharmaceutical products. The core function of methylphenidate is to serve as a research tool for studying the effects of stimulants on cognitive and physiological processes.
2
Cocaine hydrochloride by Merck Group
Sourced in United States, Germany, China, Sao Tome and Principe
Cocaine hydrochloride is a chemical compound that is used in various laboratory settings. It is a crystalline powder that is soluble in water and has a bitter taste. The core function of cocaine hydrochloride is as a local anesthetic and a stimulant. It is used in research and analysis applications.
3
Methylphenidate hcl by Merck Group
Sourced in United States
Methylphenidate HCl is a chemical compound used in laboratory settings. It is a central nervous system stimulant that can be utilized for various research and analytical purposes. The core function of Methylphenidate HCl is to serve as a reference standard or a research tool, without making any claims about its intended use.
4
Lb983 nc100 by Berthold Technologies
Sourced in Germany
The LB983 NC100 is a laboratory equipment product from Berthold Technologies. It is a multi-channel analyzer that can detect and measure various types of radiation. The core function of the LB983 NC100 is to provide precise and reliable radiation detection and analysis capabilities for laboratory applications.
5
9 10 3h oleic acid by PerkinElmer
Sourced in Germany, United States
[9,10-3H]oleic acid is a radioactively labeled fatty acid compound used for research and analytical purposes. It serves as a tracer to study the metabolism, transport, and incorporation of oleic acid in various biological systems.
6
1 propanol c3h7oh by Merck Group
1-Propanol (C3H7OH) is a colorless, flammable liquid with a characteristic odor. It is a primary alcohol with the chemical formula C3H7OH. 1-Propanol has a molecular weight of 60.10 g/mol and a boiling point of 97.2°C (207°F).
7
L dopa 3788 by Bio-Techne
L-DOPA (3788) is a chemical compound commonly used in research and development. It is the precursor to the neurotransmitter dopamine and is a key intermediate in the biosynthesis of various catecholamines. This product is intended for laboratory use only.
8
Methylphenidate hydrochloride by Merck Group
Sourced in United States, Sao Tome and Principe
Methylphenidate hydrochloride is a chemical compound used as a laboratory reagent. It is a central nervous system stimulant and has pharmacological effects. The core function of this product is to serve as a reference standard or analytical tool for research and development purposes.
9
L 741 626 1003 by Bio-Techne
L-741,626 (1003) is a selective dopamine D1 receptor antagonist. It is a laboratory research tool used in the study of the dopamine D1 receptor and its signaling pathways.
10
Lightcycler 480 by Roche
Sourced in Switzerland, Germany, United States, China, Japan, United Kingdom, France, Belgium, Canada, Australia, Sweden, Austria, Denmark, Italy, Norway, Estonia, Spain, Morocco, New Zealand, Netherlands, Czechia
The LightCycler 480 is a real-time PCR instrument designed for quantitative nucleic acid analysis. It features a 96-well format and uses high-performance optics and detection technology to provide accurate and reliable results. The core function of the LightCycler 480 is to facilitate real-time PCR experiments through thermal cycling, fluorescence detection, and data analysis.

More about "Methylphenidate"

Methylphenidate is a central nervous system (CNS) stimulant primarily used to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
It works by increasing the availability of certain neurotransmitters like dopamine and norepinephrine in the brain, helping to improve focus, concentration, and wakefulness.
This psychostimulant medication, also known as Ritalin or Concerta, is a popular choice for managing ADHD symptoms in both children and adults.
Closely related compounds include Cocaine hydrochloride, Methylphenidate HCl, and LB983 NC100, which share similar mechanisms of action and therapeutic applications.
PubCompare.ai is a valuable tool for optimizing Methylphenidate research.
Its AI-driven comparisons help users identify the most reliable protocols from the available literature, preprints, and patents.
This enhances the reproducibility and accuracy of Methylphenidate studies, ensuring researchers can find the best products and methodologies for their specific needs.
Beyond ADHD and narcolepsy, Methylphenidate has been investigated for its potential use in treating other conditions, such as cognitive impairment, depression, and Parkinson's disease.
Researchers have also explored the use of radiolabeled forms of the drug, like [9,10-3H]oleic acid, to study its pharmacokinetics and distribution in the body.
Proper storage and handling of Methylphenidate, including the use of solvents like 1-Propanol (C3H7OH), is crucial to maintain the integrity and potency of the drug.
Additionally, the use of analytical techniques, such as those involving the LightCycler 480, can aid in the quantification and characterization of Methylphenidate and its metabolites.
Overall, Methylphenidate is a versatile and widely-used CNS stimulant, and the insights provided by PubCompare.ai can help researchers optimize their Methylphenidate studies and unlock new discoveries in the field of ADHD, narcolepsy, and beyond.